EGFR and central nervous system cancer: Clinical results with rapamycin (10) have been described in patients with high-grade GBM [140, 141] and have demonstrated that treatment with rapamycin or combination with EGFR inhibitors may provide an alternative treatment for TMZ-resistant gliomas, regardless of EGFR status [134, 142].